Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Alprazolam
Drug ID BADD_D00085
Description Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms.[A18125] Alprazolam's adverse effects are generally related to the sedation it can cause.[A18125] Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death.[A18125] Alprazolam was given FDA approval on October 16, 1981.[L6148]
Indications and Usage For the management of anxiety disorder or the short-term relief of symptoms of anxiety and for the treatment of panic disorder, with or without agoraphobia.
Marketing Status Prescription; Discontinued
ATC Code N05BA12
DrugBank ID DB00404
KEGG ID D00225
MeSH ID D000525
PubChem ID 2118
TTD Drug ID D0L9GG
NDC Product Code 71335-1092; 12828-0040; 72189-029; 70954-511; 71335-1576; 0781-1061; 71335-1386; 53002-3950; 61919-836; 0009-0094; 65862-676; 53002-0340; 60760-550; 0228-4019; 72789-024; 0228-3086; 68071-4855; 50090-5257; 72789-087; 72189-058; 50090-5262; 0228-2039; 65862-677; 70954-510; 53002-4181; 68071-5243; 0615-8216; 68788-7594; 80425-0100; 63629-7726; 65162-812; 65862-456; 71335-1669; 61919-379; 71335-0849; 0228-2027; 72789-151; 55154-5885; 65862-679; 50090-5258; 72189-213; 65162-813; 55700-671; 50090-1759; 72189-240; 57218-312; 72789-042; 0228-2029; 71335-1894; 0781-1089; 71335-1839; 71335-1291; 71610-113; 45865-424; 70954-508; 61919-005; 71205-284; 68071-4818; 51991-705; 71335-0920; 65162-810; 80425-0110; 50090-5078; 59762-3721; 63187-971; 68788-7595; 51991-707; 72189-121; 0009-0066; 53002-3952; 64980-398; 59762-0059; 66267-564; 71335-1477; 42816-0090; 67296-0958; 65862-678; 53002-4180; 0228-3083; 0904-5860; 63187-518; 45865-993; 65862-455; 0054-3068; 65862-457; 60429-504; 68788-7596; 67544-347; 63629-8164; 0009-0057; 50090-4950; 61919-849; 49999-032; 64980-399; 0228-4024; 0228-2031; 70934-558; 63629-8172; 67544-414; 71205-614; 49884-214; 55289-523; 68071-4621; 0009-5144; 71335-1129; 63187-445; 65862-454; 59762-0066; 80425-0161; 71205-386; 68788-9682; 68071-4652; 70934-815; 51991-706; 0009-0068; 70518-3259; 59762-3719; 43063-609; 80425-0099; 0228-3084; 0228-4025; 59762-3720; 61919-576; 0009-0055; 68071-2236; 63629-8214; 12780-4630; 64980-396; 67253-901; 0781-1077; 67253-902; 64980-397; 68071-4923; 68071-5263; 71335-0813; 71205-227; 50090-5109; 42816-0029; 49999-252; 71610-112; 49884-110; 71335-0680; 63187-443; 0228-3087; 65162-809; 67253-900; 63187-225; 71554-013; 67253-903; 71205-290; 70518-2870; 55700-929; 35356-744; 65015-634; 0781-1079; 59762-0057; 71205-652; 59762-0068; 42816-0055; 0009-0029; 51991-704; 45865-972; 68071-5128; 68071-2220; 0009-0090; 63187-916; 67296-1748; 49452-0295; 71335-0673; 49884-213; 68071-4831; 63187-966; 0009-0059; 50090-5261; 63187-444; 50090-2781; 55700-312; 71335-1907; 59762-3722; 70954-509; 64330-013; 71335-0427; 0228-4022; 68788-7613; 68071-5113; 67544-415; 70518-2785; 0615-8295; 51655-266; 49884-111
Synonyms Alprazolam | Alprazolan | Trankimazin | U-31,889 | U31,889 | Xanax | Alprox | Esparon | Cassadan | D-65MT | D65MT | Kalma | Novo-Alprazol | Novo Alprazol | Nu-Alpraz | Nu Alpraz | Ralozam | Tafil | Apo-Alpraz | Apo Alpraz
Chemical Information
Molecular Formula C17H13ClN4
CAS Registry Number 28981-97-7
SMILES CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Anterograde amnesiaTranslocator proteinP30536T754409467187; 12798263; 9500121; 10803407; 9698157; 1668111; 14723318; 11968060
Anterograde amnesiaPlatelet-activating factor receptorP25105T870239467187; 12798263; 9500121; 10803407; 9698157; 1668111; 14723318; 11968060
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperbilirubinaemia01.06.04.003; 09.01.01.003; 14.11.01.010--Not Available
Hypercalcaemia14.04.01.003; 05.04.01.002--
Hypercapnia22.02.02.002; 14.01.04.0010.000334%Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.0280.001338%
Hyperkalaemia14.05.03.001--
Hyperlactacidaemia14.01.01.0060.000125%Not Available
Hyperprolactinaemia05.03.01.002--Not Available
Hyperreflexia17.02.01.0020.000125%Not Available
Hypersensitivity10.01.03.003--
Hypersomnia19.02.05.001; 17.15.01.0010.000334%
Hypertension24.08.02.001--
Hypertensive crisis24.08.01.0010.000334%Not Available
Hyperthyroidism14.11.01.011; 05.02.02.001--
Hypertonia17.05.02.001; 15.05.04.0070.000167%Not Available
Hyperventilation22.02.01.006; 19.01.02.0040.000125%Not Available
Hypoaesthesia17.02.06.023--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.000502%
Hypokalaemia14.05.03.0020.000836%
Hypokinesia17.01.02.0090.000543%Not Available
Hypomania19.16.02.001--Not Available
Hyponatraemia14.05.04.0020.001003%
Hyporeflexia17.02.01.0030.000167%
Hypotension24.06.03.0020.005016%
Hypothermia08.05.01.003; 12.05.03.0010.000334%
Hypotonia17.05.02.002; 15.05.04.0080.000585%Not Available
Hypoventilation22.02.01.0070.000502%Not Available
Hypoxia22.02.02.0030.000376%
Ileus07.13.01.001--
Incoherent19.10.03.006; 17.02.08.0020.000251%Not Available
The 10th Page    First    Pre   10 11 12 13 14    Next   Last    Total 25 Pages